EdgarLookup

TOFUTTI BRANDS INC — Financial Data

Annual figures from SEC EDGAR XBRL filings (10-K)

These figures are extracted directly from XBRL-tagged financial statements that TOFUTTI BRANDS INC filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.

Overview All Filings Annual Quarterly Insiders
-5.5%
Profit Margin
Net income ÷ revenue
-23%
Return on Assets
Net income ÷ assets
0.53x
Debt-to-Equity
Total liabilities ÷ equity
-2.5%
Revenue Growth
Year over year

Revenue

Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.

Fiscal Year Period End Value Filed
FY2017 Dec 30, 2017 $14.11M Mar 29, 2018
FY2017 Dec 31, 2016 $14.47M Mar 29, 2018
FY2016 Jan 2, 2016 $13.76M Mar 31, 2017
FY2015 Dec 27, 2014 $14.35M Apr 1, 2016

Revenue

Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.

Fiscal Year Period End Value Filed
FY2025 Dec 27, 2025 $7.78M Apr 13, 2026
FY2025 Dec 28, 2024 $8.82M Apr 13, 2026
FY2024 Dec 30, 2023 $10.07M Mar 31, 2025
FY2023 Dec 31, 2022 $12.83M Apr 3, 2024
FY2022 Jan 1, 2022 $12.59M Mar 31, 2023
FY2022 Jan 2, 2021 $13.82M Apr 1, 2022
FY2020 Dec 28, 2019 $13.13M Apr 19, 2021
FY2019 Dec 29, 2018 $13.07M Apr 21, 2020
FY2018 Dec 30, 2017 $14.11M Mar 29, 2019

Revenue (Net Sales)

Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.

Fiscal Year Period End Value Filed
FY2013 Dec 28, 2013 $14.69M Mar 28, 2014
FY2013 Dec 29, 2012 $14.34M Mar 28, 2014
FY2011 Dec 31, 2011 $15.93M Apr 5, 2012
FY2011 Jan 1, 2011 $17.71M Apr 5, 2012

Gross Profit

Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.

Fiscal Year Period End Value Filed
FY2025 Dec 27, 2025 $2.05M Apr 13, 2026
FY2025 Dec 28, 2024 $2.25M Apr 13, 2026
FY2024 Dec 30, 2023 $2.80M Mar 31, 2025
FY2023 Dec 31, 2022 $2.34M Apr 3, 2024
FY2022 Jan 1, 2022 $3.34M Mar 31, 2023
FY2022 Jan 2, 2021 $4.25M Apr 1, 2022
FY2020 Dec 28, 2019 $4.04M Apr 19, 2021
FY2019 Dec 29, 2018 $4.10M Apr 21, 2020
FY2018 Dec 30, 2017 $4.74M Mar 29, 2019
FY2017 Dec 31, 2016 $4.59M Mar 29, 2018

Net Income

The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.

Fiscal Year Period End Value Filed
FY2025 Dec 27, 2025 ($778.0K) Apr 13, 2026
FY2025 Dec 28, 2024 ($860.0K) Apr 13, 2026
FY2024 Dec 30, 2023 ($366.0K) Mar 31, 2025
FY2023 Dec 31, 2022 ($525.0K) Apr 3, 2024
FY2022 Jan 1, 2022 $143.0K Mar 31, 2023
FY2022 Jan 2, 2021 $596.0K Apr 1, 2022
FY2020 Dec 28, 2019 $78.0K Apr 19, 2021
FY2019 Dec 29, 2018 $507.0K Apr 21, 2020
FY2018 Dec 30, 2017 $704.0K Mar 29, 2019
FY2017 Dec 31, 2016 $421.0K Mar 29, 2018

Operating Income

Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.

Fiscal Year Period End Value Filed
FY2025 Dec 27, 2025 ($773.0K) Apr 13, 2026
FY2025 Dec 28, 2024 ($607.0K) Apr 13, 2026
FY2024 Dec 30, 2023 ($238.0K) Mar 31, 2025
FY2023 Dec 31, 2022 ($916.0K) Apr 3, 2024
FY2022 Jan 1, 2022 $242.0K Mar 31, 2023
FY2022 Jan 2, 2021 $876.0K Apr 1, 2022
FY2020 Dec 28, 2019 $108.0K Apr 19, 2021
FY2019 Dec 29, 2018 $372.0K Apr 21, 2020
FY2018 Dec 30, 2017 $750.0K Mar 29, 2019
FY2017 Dec 31, 2016 $475.0K Mar 29, 2018

R&D Expense

Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.

Fiscal Year Period End Value Filed
FY2025 Dec 27, 2025 $156.0K Apr 13, 2026
FY2025 Dec 28, 2024 $132.0K Apr 13, 2026
FY2024 Dec 30, 2023 $166.0K Mar 31, 2025
FY2023 Dec 31, 2022 $143.0K Apr 3, 2024
FY2022 Jan 1, 2022 $124.0K Mar 31, 2023
FY2022 Jan 2, 2021 $240.0K Apr 1, 2022
FY2020 Dec 28, 2019 $324.0K Apr 19, 2021
FY2019 Dec 29, 2018 $410.0K Apr 21, 2020
FY2018 Dec 30, 2017 $393.0K Mar 29, 2019
FY2017 Dec 31, 2016 $426.0K Mar 29, 2018

Operating Cash Flow

Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.

Fiscal Year Period End Value Filed
FY2025 Dec 27, 2025 ($98.0K) Apr 13, 2026
FY2025 Dec 28, 2024 ($358.0K) Apr 13, 2026
FY2024 Dec 30, 2023 ($225.0K) Mar 31, 2025
FY2023 Dec 31, 2022 ($616.0K) Apr 3, 2024
FY2022 Jan 1, 2022 $689.0K Mar 31, 2023
FY2022 Jan 2, 2021 $780.0K Apr 1, 2022
FY2020 Dec 28, 2019 ($15.0K) Apr 19, 2021
FY2019 Dec 29, 2018 ($725.0K) Apr 21, 2020
FY2018 Dec 30, 2017 $1.29M Mar 29, 2019
FY2017 Dec 31, 2016 ($418.0K) Mar 29, 2018

Capital Expenditures (Capex)

Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.

Fiscal Year Period End Value Filed
FY2020 Dec 28, 2019 $29.0K Apr 19, 2021
FY2019 Dec 29, 2018 $121.0K Apr 21, 2020

Total Assets

The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.

Fiscal Year Period End Value Filed
FY2025 Dec 27, 2025 $3.38M Apr 13, 2026
FY2025 Dec 28, 2024 $3.82M Apr 13, 2026
FY2024 Dec 30, 2023 $4.62M Mar 31, 2025
FY2023 Dec 31, 2022 $5.52M Apr 3, 2024
FY2022 Jan 1, 2022 $5.34M Mar 31, 2023
FY2022 Jan 2, 2021 $6.08M Apr 1, 2022
FY2020 Dec 28, 2019 $5.03M Apr 19, 2021
FY2019 Dec 29, 2018 $4.89M Apr 21, 2020
FY2018 Dec 30, 2017 $4.85M Mar 29, 2019
FY2017 Dec 31, 2016 $4.52M Mar 29, 2018

Total Liabilities

All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.

Fiscal Year Period End Value Filed
FY2025 Dec 27, 2025 $1.18M Apr 13, 2026
FY2025 Dec 28, 2024 $837.0K Apr 13, 2026
FY2024 Dec 30, 2023 $823.0K Mar 31, 2025
FY2023 Dec 31, 2022 $1.42M Apr 3, 2024
FY2022 Jan 1, 2022 $775.0K Mar 31, 2023
FY2022 Jan 2, 2021 $1.66M Apr 1, 2022
FY2020 Dec 28, 2019 $1.20M Apr 19, 2021
FY2019 Dec 29, 2018 $1.14M Apr 21, 2020
FY2018 Dec 30, 2017 $1.61M Mar 29, 2019
FY2017 Dec 31, 2016 $2.05M Mar 29, 2018

Stockholders Equity

The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.

Fiscal Year Period End Value Filed
FY2025 Dec 27, 2025 $2.21M Apr 13, 2026
FY2025 Dec 28, 2024 $2.99M Apr 13, 2026
FY2025 Dec 30, 2023 $3.79M Apr 13, 2026
FY2024 Dec 31, 2022 $4.10M Mar 31, 2025
FY2023 Jan 1, 2022 $4.57M Apr 3, 2024
FY2022 Jan 2, 2021 $4.42M Mar 31, 2023
FY2022 Dec 28, 2019 $3.83M Apr 1, 2022
FY2020 Dec 29, 2018 $3.75M Apr 19, 2021
FY2019 Dec 30, 2017 $3.24M Apr 21, 2020
FY2018 Dec 31, 2016 $2.47M Mar 29, 2019

Retained Earnings

Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.

Fiscal Year Period End Value Filed
FY2025 Dec 27, 2025 $1.78M Apr 13, 2026
FY2025 Dec 28, 2024 $2.56M Apr 13, 2026
FY2024 Dec 30, 2023 $3.42M Mar 31, 2025
FY2023 Dec 31, 2022 $3.78M Apr 3, 2024
FY2022 Jan 1, 2022 $4.31M Mar 31, 2023
FY2022 Jan 2, 2021 $4.17M Apr 1, 2022
FY2020 Dec 28, 2019 $3.57M Apr 19, 2021
FY2019 Dec 29, 2018 $3.49M Apr 21, 2020
FY2018 Dec 30, 2017 $2.98M Mar 29, 2019
FY2017 Dec 31, 2016 $2.28M Mar 29, 2018

Cash & Equivalents

Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.

Fiscal Year Period End Value Filed
FY2019 Dec 28, 2019 $514.0K Apr 21, 2020
FY2019 Dec 29, 2018 $558.0K Apr 21, 2020
FY2018 Dec 30, 2017 $1.41M Mar 29, 2019
FY2018 Dec 31, 2016 $132.0K Mar 29, 2019
FY2017 Jan 2, 2016 $55.0K Mar 29, 2018
FY2016 Dec 27, 2014 $341.0K Mar 31, 2017
FY2015 Dec 28, 2013 $214.0K Apr 1, 2016
FY2014 Dec 29, 2012 $471.0K Mar 27, 2015
FY2013 Dec 31, 2011 $1.59M Mar 28, 2014
FY2011 Jan 1, 2011 $2.53M Apr 5, 2012

EPS (Basic)

Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.

Fiscal Year Period End Value Filed
FY2025 Dec 27, 2025 0 Apr 13, 2026
FY2025 Dec 28, 2024 0 Apr 13, 2026
FY2024 Dec 30, 2023 0 Mar 31, 2025
FY2023 Dec 31, 2022 0 Apr 3, 2024
FY2022 Jan 1, 2022 0 Mar 31, 2023
FY2022 Jan 2, 2021 0 Apr 1, 2022
FY2020 Dec 28, 2019 0 Apr 19, 2021
FY2013 Dec 28, 2013 0 Mar 28, 2014
FY2013 Dec 29, 2012 0 Mar 28, 2014
FY2011 Dec 31, 2011 0 Apr 5, 2012

EPS (Diluted)

Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.

Fiscal Year Period End Value Filed
FY2025 Dec 27, 2025 0 Apr 13, 2026
FY2025 Dec 28, 2024 0 Apr 13, 2026
FY2024 Dec 30, 2023 0 Mar 31, 2025
FY2023 Dec 31, 2022 0 Apr 3, 2024
FY2022 Jan 1, 2022 0 Mar 31, 2023
FY2022 Jan 2, 2021 0 Apr 1, 2022
FY2020 Dec 28, 2019 0 Apr 19, 2021
FY2013 Dec 28, 2013 0 Mar 28, 2014
FY2013 Dec 29, 2012 0 Mar 28, 2014
FY2011 Dec 31, 2011 0 Apr 5, 2012

Shares Outstanding

Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.

Fiscal Year Period End Value Filed
FY2025 Dec 27, 2025 5.15M Apr 13, 2026
FY2025 Dec 28, 2024 5.15M Apr 13, 2026
FY2024 Dec 30, 2023 5.15M Mar 31, 2025
FY2023 Dec 31, 2022 5.15M Apr 3, 2024
FY2022 Jan 1, 2022 5.15M Mar 31, 2023
FY2022 Jan 2, 2021 5.15M Apr 1, 2022
FY2020 Dec 28, 2019 5.15M Apr 19, 2021
FY2019 Dec 29, 2018 5.15M Apr 21, 2020
FY2018 Dec 30, 2017 5.15M Mar 29, 2019
FY2017 Dec 31, 2016 5.15M Mar 29, 2018